Suppliers / Meghmani

Meghmani

India 293 employees Updated 9 July 2026

Meghmani is an API manufacturer based in India. It holds 3 active US drug master files and 2 valid CEPs. Its GMP standing is certified by CDSCO (India) and US FDA. Its most recent recorded inspection, by US FDA, closed on 3 February 2026 as VAI.

3
active US DMFs
2
valid CEPs
5
registered plants 2 with an FDA FEI number
1
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
2 of 2 confirmed
Inspections
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 3 February 2026 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Ahmedabad, India Not on file
Dahej, India 3030599291
Dahej, India Not on file
Bharuch, India 3005404478
Dahej, India Not on file

What they file, and where

Molecule Regulators Docs
Acetaminophen EDQM, US FDA 5

Also appears on these molecule pages

Paracetamol API

Filings and GMP by regulator

Regulator Filings GMP certificates
MINSA (CR) 1 None
CDSCO (India) None 2
US FDA None 1

Comparing suppliers?

Choose your molecules and target markets. Meghmani comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 3 February 2026.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates